Immunic, INC. 8-K Filing
Ticker: IMUX · Form: 8-K · Filed: Apr 1, 2026 · CIK: 0001280776
| Field | Detail |
|---|---|
| Company | Immunic, INC. (IMUX) |
| Form Type | 8-K |
| Filed Date | Apr 1, 2026 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $1.00 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Immunic, INC. (ticker: IMUX) to the SEC on Apr 1, 2026.
What are the key financial figures in this filing?
Key dollar amounts include: $0.0001 (ch registered Common Stock, par value $0.0001 IMUX The Nasdaq Stock Market LLC I); $1.00 (ar value $0.0001 per share, of at least $1.00 per share for the 20 consecutive busine).
How long is this filing?
Immunic, INC.'s 8-K filing is 2 pages with approximately 513 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 513 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2026-04-01 07:00:32
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 IMUX The Nasdaq Stock Market LLC I
- $1.00 — ar value $0.0001 per share, of at least $1.00 per share for the 20 consecutive busine
Filing Documents
- e665306_8k-immunic.htm (8-K) — 21KB
- e665306_ex99-1.htm (EX-99.1) — 10KB
- image_001.jpg (GRAPHIC) — 3KB
- 0001193805-26-000382.txt ( ) — 201KB
- imux-20260327.xsd (EX-101.SCH) — 3KB
- imux-20260327_lab.xml (EX-101.LAB) — 33KB
- imux-20260327_pre.xml (EX-101.PRE) — 22KB
- e665306_8k-immunic_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On March 27, 2026, Immunic, Inc. (the "Company") received a written notification (the "Nasdaq Letter") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that Nasdaq has determined that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2)(the "Minimum Bid Price Requirement") by maintaining a minimum closing bid price of the Company's common stock, par value $0.0001 per share, of at least $1.00 per share for the 20 consecutive business days, from February 27, 2026 to March 26, 2026, and that this matter is now closed. On April 1, 2026, the Company issued a press release announcing the receipt of the Nasdaq Letter and that the Company had regained compliance with the Minimum Bid Price Requirement. A copy of the press release issued by the Company is attached hereto as Exhibit 99.1 and is incorporated by reference into this Item 8.01.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits Exhibit Description 99.1 Press Release, dated April 1, 2026 104 Cover Page to this Current Report on Form 8-K in Inline XBRL
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Dated: April 1, 2026 Immunic, Inc. By: /s/ Daniel Vitt Daniel Vitt Chief Executive Officer